Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "G-20"

123 News Found

Indian pharma’s vaccine opportunity at US $ 10-11 billion
Biotech | August 17, 2021

Indian pharma’s vaccine opportunity at US $ 10-11 billion

Domestic market and developing countries will need doses of Indian vaccines

Govt. monitoring supply of COVID-19 essential drugs
News | May 21, 2021

Govt. monitoring supply of COVID-19 essential drugs

Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.

Indian vaccine players to garner Rs. 70,599 Cr in 2021
News | April 30, 2021

Indian vaccine players to garner Rs. 70,599 Cr in 2021

Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru

Teva submits FDA application for experimental Tourette syndrome treatment ecopipam

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging